11-557617-C-A
Position:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_173573.3(LMNTD2):c.579G>T(p.Met193Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000779 in 1,613,232 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 11/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.00032 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00083 ( 2 hom. )
Consequence
LMNTD2
NM_173573.3 missense
NM_173573.3 missense
Scores
1
16
Clinical Significance
Conservation
PhyloP100: -0.459
Genes affected
LMNTD2 (HGNC:28561): (lamin tail domain containing 2) Predicted to be a structural constituent of chromatin. Predicted to be involved in regulation of chromatin assembly. Predicted to act upstream of or within positive regulation of mRNA splicing, via spliceosome. Predicted to be active in lamin filament. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.035343975).
BS2
High Homozygotes in GnomAdExome4 at 2 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LMNTD2 | NM_173573.3 | c.579G>T | p.Met193Ile | missense_variant | 6/14 | ENST00000329451.8 | NP_775844.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LMNTD2 | ENST00000329451.8 | c.579G>T | p.Met193Ile | missense_variant | 6/14 | 1 | NM_173573.3 | ENSP00000331167.3 | ||
LMNTD2 | ENST00000441853.5 | c.600G>T | p.Met200Ile | missense_variant | 7/9 | 3 | ENSP00000393529.1 | |||
LMNTD2 | ENST00000486629.1 | c.609G>T | p.Met203Ile | missense_variant | 6/7 | 5 | ENSP00000435529.1 | |||
LMNTD2-AS1 | ENST00000527620.5 | n.23C>A | non_coding_transcript_exon_variant | 1/2 | 2 |
Frequencies
GnomAD3 genomes AF: 0.000322 AC: 49AN: 152180Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
49
AN:
152180
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000260 AC: 65AN: 250348Hom.: 0 AF XY: 0.000236 AC XY: 32AN XY: 135618
GnomAD3 exomes
AF:
AC:
65
AN:
250348
Hom.:
AF XY:
AC XY:
32
AN XY:
135618
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000826 AC: 1207AN: 1460934Hom.: 2 Cov.: 36 AF XY: 0.000795 AC XY: 578AN XY: 726748
GnomAD4 exome
AF:
AC:
1207
AN:
1460934
Hom.:
Cov.:
36
AF XY:
AC XY:
578
AN XY:
726748
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000322 AC: 49AN: 152298Hom.: 0 Cov.: 33 AF XY: 0.000376 AC XY: 28AN XY: 74480
GnomAD4 genome
AF:
AC:
49
AN:
152298
Hom.:
Cov.:
33
AF XY:
AC XY:
28
AN XY:
74480
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
TwinsUK
AF:
AC:
3
ALSPAC
AF:
AC:
3
ExAC
AF:
AC:
27
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 09, 2021 | The c.579G>T (p.M193I) alteration is located in exon 6 (coding exon 6) of the LMNTD2 gene. This alteration results from a G to T substitution at nucleotide position 579, causing the methionine (M) at amino acid position 193 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T;T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T;T
M_CAP
Benign
T
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
PROVEAN
Benign
N;D;D
REVEL
Benign
Sift
Benign
D;D;T
Sift4G
Benign
T;T;.
Polyphen
B;.;.
Vest4
MutPred
Gain of catalytic residue at L198 (P = 0.0212);.;.;
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at